Want to see OSTX full AI Analyst Report?
OSTX Stock Chart & Stats
$1.52
$0.01(0.66%)
At close: 4:00 PM EDT
$1.52
$0.01(0.66%)
Day’s Range― - ―
52-Week Range$1.15 - $2.57
Previous Close$1.56
Volume216.20K
Average Volume (3M)735.57K
Market Cap
$69.22M
Enterprise Value$56.03
Total Cash (Recent Filing)$917.55K
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 13, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding45,538,100
10 Day Avg. Volume409,704
30 Day Avg. Volume735,574
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.67Price Target Upside470.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$2.67M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressA formal EMA rolling review, regulator alignment on three-year overall survival endpoints, selection for the EMA Raw Data Pilot, and U.K. ATMP designation materially reduce regulatory uncertainty. These structural approvals streamline a coordinated global Phase 3 and increase odds of conditional approval and market access over the next 6–12 months.
Secured Bridge Financing & GovernanceThe secured convertible note facility with an initial tranche funded provides near-term funding without immediate broad equity dilution and preserves IP collateralization. Coupled with appointment of an experienced oncology executive to the board, this strengthens funding runway into 2027 and clinical/regulatory execution capacity for late-stage work.
Stronger Capital Base (TTM)The transition to a materially larger asset base and restored positive equity versus prior negative periods gives the company a more robust capital foundation. This structural improvement supports continued R&D investment and absorbs development volatility better than earlier balance-sheet-constrained years, aiding long-term program funding.
Bears Say
Pre-revenue, Persistent LossesThe company remains pre-revenue with persistent negative gross profit and a sharp expansion of operating losses in the latest period. This structural lack of commercial cash inflow means ongoing reliance on external capital to fund operations, increasing dilution risk and tying corporate health to successful trial and approval milestones.
Elevated LeverageMaterially higher debt and negative return on equity create structural financial constraints. Elevated leverage reduces strategic flexibility, increases covenant and interest sensitivity, and magnifies downside if clinical timelines slip or approvals are delayed, potentially forcing tougher financing terms or asset-linked borrowing in the medium term.
Cash Burn And Reduced Financing FlexibilityConsistent negative operating and free cash flow means the business is not self-funding and needs external capital. Termination of the $18M ATM program removes a previously available, flexible equity tap, increasing dependence on negotiated financings with stricter terms and raising execution risk if funding windows narrow before approvals or milestones.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.15 and its highest was $2.57 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $69.22M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Aug 13, 2026 which is in 10 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on May 18, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.18.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 45,538,100 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.979%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (470.18% Upside)
$8.67 (470.18% Upside)
Blogger Sentiment
Bullish
OSTX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
71.75%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$8.67
▲(470.18% Upside)
Technical Analysis
Ownership Overview
8.12% Insiders
1.51% Mutual Funds
0.54% Other Institutional Investors
87.78% Public Companies and
Individual Investors